Inactivation of three emerging viruses - severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus - in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light.
Identifieur interne : 000442 ( PubMed/Checkpoint ); précédent : 000441; suivant : 000443Inactivation of three emerging viruses - severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus - in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light.
Auteurs : Markus Eickmann [Allemagne] ; Ute Gravemann [Allemagne] ; Wiebke Handke [Allemagne] ; Frank Tolksdorf [Allemagne] ; Stefan Reichenberg [Allemagne] ; Thomas H. Müller [Allemagne] ; Axel Seltsam [Allemagne]Source :
- Vox sanguinis [ 1423-0410 ] ; 2020.
Abstract
Emerging viruses like severe acute respiratory syndrome coronavirus (SARS-CoV), Crimean-Congo haemorrhagic fever virus (CCHFV) and Nipah virus (NiV) have been identified to pose a potential threat to transfusion safety. In this study, the ability of the THERAFLEX UV-Platelets and THERAFLEX MB-Plasma pathogen inactivation systems to inactivate these viruses in platelet concentrates and plasma, respectively, was investigated.
DOI: 10.1111/vox.12888
PubMed: 31930543
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:31930543Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inactivation of three emerging viruses - severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus - in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light.</title><author><name sortKey="Eickmann, Markus" sort="Eickmann, Markus" uniqKey="Eickmann M" first="Markus" last="Eickmann">Markus Eickmann</name><affiliation wicri:level="3"><nlm:affiliation>Institute for Virology, Philipps University Marburg, Marburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute for Virology, Philipps University Marburg, Marburg</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Gravemann, Ute" sort="Gravemann, Ute" uniqKey="Gravemann U" first="Ute" last="Gravemann">Ute Gravemann</name><affiliation wicri:level="1"><nlm:affiliation>German Red Cross Blood Service NSTOB, Springe, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>German Red Cross Blood Service NSTOB, Springe</wicri:regionArea><wicri:noRegion>Springe</wicri:noRegion><wicri:noRegion>Springe</wicri:noRegion><wicri:noRegion>Springe</wicri:noRegion></affiliation></author><author><name sortKey="Handke, Wiebke" sort="Handke, Wiebke" uniqKey="Handke W" first="Wiebke" last="Handke">Wiebke Handke</name><affiliation wicri:level="1"><nlm:affiliation>German Red Cross Blood Service NSTOB, Springe, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>German Red Cross Blood Service NSTOB, Springe</wicri:regionArea><wicri:noRegion>Springe</wicri:noRegion><wicri:noRegion>Springe</wicri:noRegion><wicri:noRegion>Springe</wicri:noRegion></affiliation></author><author><name sortKey="Tolksdorf, Frank" sort="Tolksdorf, Frank" uniqKey="Tolksdorf F" first="Frank" last="Tolksdorf">Frank Tolksdorf</name><affiliation wicri:level="1"><nlm:affiliation>Maco Pharma International GmbH, Langen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Maco Pharma International GmbH, Langen</wicri:regionArea><wicri:noRegion>Langen</wicri:noRegion><wicri:noRegion>Langen</wicri:noRegion><wicri:noRegion>Langen</wicri:noRegion></affiliation></author><author><name sortKey="Reichenberg, Stefan" sort="Reichenberg, Stefan" uniqKey="Reichenberg S" first="Stefan" last="Reichenberg">Stefan Reichenberg</name><affiliation wicri:level="1"><nlm:affiliation>Maco Pharma International GmbH, Langen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Maco Pharma International GmbH, Langen</wicri:regionArea><wicri:noRegion>Langen</wicri:noRegion><wicri:noRegion>Langen</wicri:noRegion><wicri:noRegion>Langen</wicri:noRegion></affiliation></author><author><name sortKey="Muller, Thomas H" sort="Muller, Thomas H" uniqKey="Muller T" first="Thomas H" last="Müller">Thomas H. Müller</name><affiliation wicri:level="1"><nlm:affiliation>German Red Cross Blood Service NSTOB, Springe, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>German Red Cross Blood Service NSTOB, Springe</wicri:regionArea><wicri:noRegion>Springe</wicri:noRegion><wicri:noRegion>Springe</wicri:noRegion><wicri:noRegion>Springe</wicri:noRegion></affiliation></author><author><name sortKey="Seltsam, Axel" sort="Seltsam, Axel" uniqKey="Seltsam A" first="Axel" last="Seltsam">Axel Seltsam</name><affiliation wicri:level="1"><nlm:affiliation>German Red Cross Blood Service NSTOB, Springe, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>German Red Cross Blood Service NSTOB, Springe</wicri:regionArea><wicri:noRegion>Springe</wicri:noRegion><wicri:noRegion>Springe</wicri:noRegion><wicri:noRegion>Springe</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:31930543</idno><idno type="pmid">31930543</idno><idno type="doi">10.1111/vox.12888</idno><idno type="wicri:Area/PubMed/Corpus">000848</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000848</idno><idno type="wicri:Area/PubMed/Curation">000848</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000848</idno><idno type="wicri:Area/PubMed/Checkpoint">000442</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000442</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Inactivation of three emerging viruses - severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus - in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light.</title><author><name sortKey="Eickmann, Markus" sort="Eickmann, Markus" uniqKey="Eickmann M" first="Markus" last="Eickmann">Markus Eickmann</name><affiliation wicri:level="3"><nlm:affiliation>Institute for Virology, Philipps University Marburg, Marburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute for Virology, Philipps University Marburg, Marburg</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Gravemann, Ute" sort="Gravemann, Ute" uniqKey="Gravemann U" first="Ute" last="Gravemann">Ute Gravemann</name><affiliation wicri:level="1"><nlm:affiliation>German Red Cross Blood Service NSTOB, Springe, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>German Red Cross Blood Service NSTOB, Springe</wicri:regionArea><wicri:noRegion>Springe</wicri:noRegion><wicri:noRegion>Springe</wicri:noRegion><wicri:noRegion>Springe</wicri:noRegion></affiliation></author><author><name sortKey="Handke, Wiebke" sort="Handke, Wiebke" uniqKey="Handke W" first="Wiebke" last="Handke">Wiebke Handke</name><affiliation wicri:level="1"><nlm:affiliation>German Red Cross Blood Service NSTOB, Springe, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>German Red Cross Blood Service NSTOB, Springe</wicri:regionArea><wicri:noRegion>Springe</wicri:noRegion><wicri:noRegion>Springe</wicri:noRegion><wicri:noRegion>Springe</wicri:noRegion></affiliation></author><author><name sortKey="Tolksdorf, Frank" sort="Tolksdorf, Frank" uniqKey="Tolksdorf F" first="Frank" last="Tolksdorf">Frank Tolksdorf</name><affiliation wicri:level="1"><nlm:affiliation>Maco Pharma International GmbH, Langen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Maco Pharma International GmbH, Langen</wicri:regionArea><wicri:noRegion>Langen</wicri:noRegion><wicri:noRegion>Langen</wicri:noRegion><wicri:noRegion>Langen</wicri:noRegion></affiliation></author><author><name sortKey="Reichenberg, Stefan" sort="Reichenberg, Stefan" uniqKey="Reichenberg S" first="Stefan" last="Reichenberg">Stefan Reichenberg</name><affiliation wicri:level="1"><nlm:affiliation>Maco Pharma International GmbH, Langen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Maco Pharma International GmbH, Langen</wicri:regionArea><wicri:noRegion>Langen</wicri:noRegion><wicri:noRegion>Langen</wicri:noRegion><wicri:noRegion>Langen</wicri:noRegion></affiliation></author><author><name sortKey="Muller, Thomas H" sort="Muller, Thomas H" uniqKey="Muller T" first="Thomas H" last="Müller">Thomas H. Müller</name><affiliation wicri:level="1"><nlm:affiliation>German Red Cross Blood Service NSTOB, Springe, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>German Red Cross Blood Service NSTOB, Springe</wicri:regionArea><wicri:noRegion>Springe</wicri:noRegion><wicri:noRegion>Springe</wicri:noRegion><wicri:noRegion>Springe</wicri:noRegion></affiliation></author><author><name sortKey="Seltsam, Axel" sort="Seltsam, Axel" uniqKey="Seltsam A" first="Axel" last="Seltsam">Axel Seltsam</name><affiliation wicri:level="1"><nlm:affiliation>German Red Cross Blood Service NSTOB, Springe, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>German Red Cross Blood Service NSTOB, Springe</wicri:regionArea><wicri:noRegion>Springe</wicri:noRegion><wicri:noRegion>Springe</wicri:noRegion><wicri:noRegion>Springe</wicri:noRegion></affiliation></author></analytic><series><title level="j">Vox sanguinis</title><idno type="eISSN">1423-0410</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Emerging viruses like severe acute respiratory syndrome coronavirus (SARS-CoV), Crimean-Congo haemorrhagic fever virus (CCHFV) and Nipah virus (NiV) have been identified to pose a potential threat to transfusion safety. In this study, the ability of the THERAFLEX UV-Platelets and THERAFLEX MB-Plasma pathogen inactivation systems to inactivate these viruses in platelet concentrates and plasma, respectively, was investigated.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">31930543</PMID><DateRevised><Year>2020</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-0410</ISSN><JournalIssue CitedMedium="Internet"><Volume>115</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Vox sanguinis</Title><ISOAbbreviation>Vox Sang.</ISOAbbreviation></Journal><ArticleTitle>Inactivation of three emerging viruses - severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus - in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light.</ArticleTitle><Pagination><MedlinePgn>146-151</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/vox.12888</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Emerging viruses like severe acute respiratory syndrome coronavirus (SARS-CoV), Crimean-Congo haemorrhagic fever virus (CCHFV) and Nipah virus (NiV) have been identified to pose a potential threat to transfusion safety. In this study, the ability of the THERAFLEX UV-Platelets and THERAFLEX MB-Plasma pathogen inactivation systems to inactivate these viruses in platelet concentrates and plasma, respectively, was investigated.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Blood products were spiked with SARS-CoV, CCHFV or NiV, and then treated with increasing doses of UVC light (THERAFLEX UV-Platelets) or with methylene blue (MB) plus increasing doses of visible light (MB/light; THERAFLEX MB-Plasma). Samples were taken before and after treatment with each illumination dose and tested for residual infectivity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Treatment with half to three-fourths of the full UVC dose (0·2 J/cm<sup>2</sup> ) reduced the infectivity of SARS-CoV (≥3·4 log), CCHFV (≥2·2 log) and NiV (≥4·3 log) to the limit of detection (LOD) in platelet concentrates, and treatment with MB and a fourth of the full light dose (120 J/cm<sup>2</sup> ) decreased that of SARS-CoV (≥3·1 log), CCHFV (≥3·2 log) and NiV (≥2·7 log) to the LOD in plasma.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our study demonstrates that both THERAFLEX UV-Platelets (UVC) and THERAFLEX MB-Plasma (MB/light) effectively reduce the infectivity of SARS-CoV, CCHFV and NiV in platelet concentrates and plasma, respectively.</AbstractText><CopyrightInformation>© 2020 International Society of Blood Transfusion.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eickmann</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Virology, Philipps University Marburg, Marburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gravemann</LastName><ForeName>Ute</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>German Red Cross Blood Service NSTOB, Springe, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Handke</LastName><ForeName>Wiebke</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>German Red Cross Blood Service NSTOB, Springe, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tolksdorf</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Maco Pharma International GmbH, Langen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reichenberg</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Maco Pharma International GmbH, Langen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Müller</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>German Red Cross Blood Service NSTOB, Springe, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seltsam</LastName><ForeName>Axel</ForeName><Initials>A</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-5858-5097</Identifier><AffiliationInfo><Affiliation>German Red Cross Blood Service NSTOB, Springe, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>German Red Cross Blood Services (Deutsche Forschungsgemeinschaft der Blutspendedienste des Deutschen Roten Kreuzes)</Agency><Country></Country></Grant><Grant><Agency>Macopharma S.A.S.</Agency><Country></Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Vox Sang</MedlineTA><NlmUniqueID>0413606</NlmUniqueID><ISSNLinking>0042-9007</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">methylene blue</Keyword><Keyword MajorTopicYN="N">pathogen inactivation</Keyword><Keyword MajorTopicYN="N">plasma</Keyword><Keyword MajorTopicYN="N">platelet concentrates</Keyword><Keyword MajorTopicYN="N">ultraviolet light</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>09</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31930543</ArticleId><ArticleId IdType="doi">10.1111/vox.12888</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Stramer SL, Hollinger FB, Katz LM, et al.: Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009; 49:1S-29S</Citation></Reference><Reference><Citation>Stramer SL: Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections. ISBT Sci Ser 2014; 9:30-6</Citation></Reference><Reference><Citation>Bahar B, Schulz WL, Gokhale A, et al.: Blood utilisation and transfusion reactions in adult patients transfused with conventional or pathogen-reduced platelets. Br J Haematol 2019. https://doi.org/10.1111/bjh.16187 [Epub ahead of print].</Citation></Reference><Reference><Citation>Seltsam A, Muller TH: Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol 2013; 162:442-54</Citation></Reference><Reference><Citation>Mohr H, Steil L, Gravemann U, et al.: A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 2009; 49:2612-24</Citation></Reference><Reference><Citation>Seltsam A, Muller TH: UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother 2011; 38:43-54</Citation></Reference><Reference><Citation>Kim S, Handke W, Gravemann U, et al.: Mitochondrial DNA multiplex real-time polymerase chain reaction inhibition assay for quality control of pathogen inactivation by ultraviolet C light in platelet concentrates. Transfusion 2018; 58:758-65</Citation></Reference><Reference><Citation>Mohr H, Lambrecht B, Selz A: Photodynamic virus inactivation of blood components. Immunol Invest 1995; 24:73-85</Citation></Reference><Reference><Citation>Seghatchian J, Walker WH, Reichenberg S: Updates on pathogen inactivation of plasma using Theraflex methylene blue system. Transfus Apher Sci 2008; 38:271-80</Citation></Reference><Reference><Citation>Politis C, Kavallierou L, Hantziara S, et al.: Haemovigilance data on the use of methylene blue virally inactivated fresh frozen plasma with the Theraflex MB-Plasma System in comparison to quarantine plasma: 11 years' experience. Transfus Med 2014; 24:316-20</Citation></Reference><Reference><Citation>Williamson LM, Cardigan R, Prowse CV: Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety? Transfusion 2003; 43:1322-9</Citation></Reference><Reference><Citation>Faddy HM, Fryk JJ, Prow NA, et al.: Inactivation of dengue, chikungunya, and Ross River viruses in platelet concentrates after treatment with ultraviolet C light. Transfusion 2016; 56:1548-55</Citation></Reference><Reference><Citation>Fryk JJ, Marks DC, Hobson-Peters J, et al.: Reduction of Zika virus infectivity in platelet concentrates after treatment with ultraviolet C light and in plasma after treatment with methylene blue and visible light. Transfusion 2017; 57:2677-82</Citation></Reference><Reference><Citation>Eickmann M, Gravemann U, Handke W, et al.: Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectively. Transfusion 2018; 58:2202-7</Citation></Reference><Reference><Citation>Arnason NA, Johannson F, Landro R, et al.: Pathogen inactivation with amotosalen plus UVA illumination minimally impacts microRNA expression in platelets during storage under standard blood banking conditions. Transfusion 2019; 59:3727-3735</Citation></Reference><Reference><Citation>Castro E, Girones N, Guerrero N, et al.: The effectiveness of UVC pathogen inactivation system on reducing the Trypansosoma cruzi and Leishmania infantum burden in platelets. Vox Sang 2008; 95:290</Citation></Reference><Reference><Citation>Castro E, Gonzalez LM, Rubio JM, et al.: The efficacy of the ultraviolet C pathogen inactivation system in the reduction of Babesia divergens in pooled buffy coat platelets. Transfusion 2014; 54:2207-16</Citation></Reference><Reference><Citation>Gravemann U, Handke W, Lambrecht B, et al.: Ultraviolet C light efficiently inactivates nonenveloped hepatitis A virus and feline calicivirus in platelet concentrates. Transfusion 2018; 58:2669-74</Citation></Reference><Reference><Citation>Gravemann U, Handke W, Muller TH, et al.: Bacterial inactivation of platelet concentrates with the THERAFLEX UV-Platelets pathogen inactivation system. Transfusion 2019; 59:1324-32</Citation></Reference><Reference><Citation>Seghatchian J, Struff WG, Reichenberg S: Main properties of the THERAFLEX MB-plasma system for pathogen reduction. Transf Med Hemother 2011; 38:55-64</Citation></Reference><Reference><Citation>Spearman C: The method of "right and wrong cases" ("constant stimuli") without Gauss's formulae. Br J Psychol 1908; 2:277-82</Citation></Reference><Reference><Citation>Kaerber G: Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1931; 162:480-3</Citation></Reference><Reference><Citation>Agafonov AP, Gus'kov AA, Ternovoi VA, et al.: Primary characterization of SARS coronavirus strain Frankfurt 1. Dokl Biol Sci 2004; 394:58-60</Citation></Reference><Reference><Citation>Olschlager S, Gabriel M, Schmidt-Chanasit J, et al.: Complete sequence and phylogenetic characterisation of Crimean-Congo hemorrhagic fever virus from Afghanistan. J Clin Virol 2011; 50:90-2</Citation></Reference><Reference><Citation>Wild TF: Henipaviruses: a new family of emerging Paramyxoviruses. Pathol Biol (Paris) 2009; 57:188-96</Citation></Reference><Reference><Citation>Woolhouse ME, Haydon DT, Antia R: Emerging pathogens: the epidemiology and evolution of species jumps. Trends Ecol Evol 2005; 20:238-44</Citation></Reference><Reference><Citation>de Wit E, van Doremalen N, Falzarano D, et al.: SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016; 14:523-34</Citation></Reference><Reference><Citation>Dunstan RA, Seed CR, Keller AJ: Emerging viral threats to the Australian blood supply. Aust N Z J Public Health 2008; 32:354-60</Citation></Reference><Reference><Citation>Bente DA, Forrester NL, Watts DM, et al.: Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antiviral Res 2013; 100:159-89</Citation></Reference><Reference><Citation>Conger NG, Paolino KM, Osborn EC, et al.: Health care response to CCHF in US soldier and nosocomial transmission to health care providers, Germany, 2009. Emerg Infect Dis 2015; 21:23-31</Citation></Reference><Reference><Citation>Sharma V, Kaushik S, Kumar R, et al.: Emerging trends of Nipah virus: A review. Rev Med Virol 2019; 29:e2010</Citation></Reference><Reference><Citation>Ang BSP, Lim TCC, Wang L: Nipah virus infection. J Clin Microbiol 201856(6):e01875-17</Citation></Reference><Reference><Citation>Nikolay B, Salje H, Hossain MJ, et al.: Transmission of nipah virus - 14 years of investigations in Bangladesh. N Engl J Med 2019; 380:1804-14</Citation></Reference><Reference><Citation>McCullough J, Alter HJ, Ness PM: Interpretation of pathogen load in relationship to infectivity and pathogen reduction efficacy. Transfusion 2019; 59:1132-46</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country><region><li>District de Giessen</li><li>Hesse (Land)</li></region><settlement><li>Marbourg</li></settlement></list><tree><country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Eickmann, Markus" sort="Eickmann, Markus" uniqKey="Eickmann M" first="Markus" last="Eickmann">Markus Eickmann</name></region><name sortKey="Gravemann, Ute" sort="Gravemann, Ute" uniqKey="Gravemann U" first="Ute" last="Gravemann">Ute Gravemann</name><name sortKey="Handke, Wiebke" sort="Handke, Wiebke" uniqKey="Handke W" first="Wiebke" last="Handke">Wiebke Handke</name><name sortKey="Muller, Thomas H" sort="Muller, Thomas H" uniqKey="Muller T" first="Thomas H" last="Müller">Thomas H. Müller</name><name sortKey="Reichenberg, Stefan" sort="Reichenberg, Stefan" uniqKey="Reichenberg S" first="Stefan" last="Reichenberg">Stefan Reichenberg</name><name sortKey="Seltsam, Axel" sort="Seltsam, Axel" uniqKey="Seltsam A" first="Axel" last="Seltsam">Axel Seltsam</name><name sortKey="Tolksdorf, Frank" sort="Tolksdorf, Frank" uniqKey="Tolksdorf F" first="Frank" last="Tolksdorf">Frank Tolksdorf</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000442 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000442 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:31930543
|texte= Inactivation of three emerging viruses - severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus - in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:31930543" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |